Approval · Notice of Compliance 34770 · 2025
ZYPREXA: Notice of Compliance 34770
Issued January 30, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34770
- Date
- January 30, 2025
- Company
- Cheplapharm Registration GmbhLörrach, Germany
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Change in product ownership and Product Monograph reformatted to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZYPREXA | 02229250 | Marketed |
| ZYPREXA | 02229269 | Marketed |
| ZYPREXA | 02229277 | Marketed |
| ZYPREXA | 02229285 | Marketed |
| ZYPREXA | 02238850 | Marketed |
| ZYPREXA | 02238851 | Marketed |
| ZYPREXA INTRAMUSCULAR | 02247099 | Marketed |
| ZYPREXA ZYDIS | 02243086 | Marketed |
| ZYPREXA ZYDIS | 02243087 | Marketed |
| ZYPREXA ZYDIS | 02243088 | Marketed |
| ZYPREXA ZYDIS | 02243089 | Marketed |
Medicinal ingredients
- OLANZAPINE 2.5 MG per TAB
- OLANZAPINE 5 MG per TAB
- OLANZAPINE 7.5 MG per TAB
- OLANZAPINE 10 MG per TAB
- OLANZAPINE 15 MG per TAB
- OLANZAPINE 20 MG per TAB
- OLANZAPINE TARTRATE 10 MG per VIAL